{
    "nct_id": "NCT06027086",
    "official_title": "A Phase 1b/2 Study of Glutamine Antagonist DRP-104 in Combination With Durvalumab in Patients With Advanced Stage Fibrolamellar Hepatocellular Carcinoma (FLC)",
    "inclusion_criteria": "* Must have histologically confirmed FLC (Fibrolamellar Carcinoma) that is metastatic or unresectable.\n* Presence of DNAJB1-PRKACA fusion transcript, assessed by RNA-sequencing, DNA-sequencing, or in situ hybridization in the archival tissue.\n* Must have demonstrated radiographic progression on prior or current immunotherapy.\n* Age ≥ 12 years.\n* Patients < 18 years old must have a body weight ≥ 40 kg.\n* Eastern Cooperative Oncology Group (ECOG) performance status of ≤2\n* Patients must have adequate organ and marrow function defined by study-specified laboratory tests.\n* Patients must have adequate kidney and liver function defined by study-specified laboratory tests.\n* Must have measurable disease per RECIST 1.1\n* Willingness to provide tissue and blood samples for mandatory translational research.\n* Women of childbearing potential (WOCBP) must have a negative urine or serum pregnancy test.\n* For both Women and Men, must use acceptable form of birth control while on study.\n* Ability to understand and willingness to sign a written informed consent document.\nHealthy volunteers allowed\nMust have minimum age of 12 Years",
    "exclusion_criteria": "* Must have had chemotherapy or other systemic therapy or radiotherapy, as follows:\n\n  * Patients who have had chemotherapy, biological cancer therapy, or radiation 21 days prior to the first dose of study drug.\n  * Patients who have had surgery within 28 days of dosing of investigational agent, excluding minor procedures.\n  * Patients who have received other approved or investigational agents or device within 21 days of the first dose of study drug.\n* Patients who have not recovered from acute adverse events to grade ≤1 or baseline due to agents administered, with exception of grade 2 fatigue, rash, and endocrinopathy successfully managed hormone replacement therapy, or alopecia or stable neuropathy, unless approved by the investigational new drug (IND) Sponsor.\n* Patients with corrected QT interval (QTc) prolongation > 470 ms according to Fridericia formula.\n* Patients receiving potent inducers of Cytochrome P450 3A (CYP 3A4/5) (including apalutamide, carbamazepine, enzalutamide, mitotane, phenytoin, rifampin and St. John's Wort) that cannot be discontinued at least 14 days prior to Cycle 1 Day 1.\n* Known sensitivity to or history of allergic reactions attributed to compounds of similar chemical or biologic composition of DRP-104 or durvalumab.\n* Subjects with interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected drug-related pulmonary toxicity.\n* Has a pulse oximetry of <92% on room air or is on supplemental home oxygen.\n* Active or untreated brain metastases or leptomeningeal metastases.\n* Uncontrolled intercurrent active medical and/or psychiatric illness/social psychosocial problems that that would limit compliance with study requirements.\n* Uncontrolled intercurrent illness including, but not limited to, uncontrolled infection, symptomatic congestive heart failure, unstable angina, cardiac arrhythmia, metastatic cancer, or psychiatric illness/social situations that would limit compliance with study requirements.\n* Pregnant or breastfeeding.\n* Has a known history of Human Immunodeficiency Virus (HIV)/AIDS.\n* Has active hepatitis B. Patients with chronic or acute hepatitis B virus (HBV) infection .\n* Have had evidence of active or acute diverticulitis, intra-abdominal abscess, or GI obstruction which are known risk factors for bowel perforation should be evaluated for the potential need for additional treatment before coming on study.\n* Patient is unwilling or unable to follow the study schedule for any reason.\n* Patient is at the time of signing informed consent a regular user (including \"recreational use\") of any illicit drugs or had a recent history (within the last year) of substance abuse (including alcohol).\n* Evidence of clinical ascites.\n* Participants a with history of prior unacceptable and/or life-threatening toxicities attributed to anti-programmed death-receptor 1 (PD1) or anti-PD-L1 (anti-programmed death-receptor 1) therapy.\n* Has active autoimmune disease that has required systemic treatment in the past 2 years.\n* Prior allogeneic stem cell transplantation or organ transplantation.\n* Has a diagnosis of immunodeficiency.\n* Systemic corticosteroids at immunosuppressive doses.\n* Patients who have had either of the following procedures or medications within 4 weeks prior to initiation of study treatment:\n* Any live, attenuated vaccine\n* Allergen hypo sensitization therapy in the last 2 weeks",
    "miscellaneous_criteria": ""
}